Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/105164
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn's disease: a pilot randomised placebo-controlled trial
Author: Mikocka-Walus, A.
Hughes, P.
Bampton, P.
Gordon, A.
Campaniello, M.
Mavrangelos, C.
Stewart, B.
Esterman, A.
Andrews, J.
Citation: Journal of Crohn's & colitis, 2017; 11(4):509-514
Publisher: Oxford University Press
Issue Date: 2017
ISSN: 1873-9946
1876-4479
Statement of
Responsibility: 
Antonina Mikocka-Walus, Patrick A. Hughes, Peter Bampton, Andrea Gordon, Melissa A. Campaniello, Chris Mavrangelos, Benjamin J. Stewart, Adrian Esterman, Jane M. Andrews
Abstract: Background and Aims: Previous studies have shown that antidepressants reduce inflammation in animal models of colitis. The present trial aimed to examine whether fluoxetine added to standard therapy for Crohn’s disease [CD] maintained remission, improved quality of life [QoL] and/or mental health in people with CD as compared to placebo. Methods: A parallel randomized double-blind placebo controlled trial was conducted. Participants with clinically established CD, with quiescent or only mild disease, were randomly assigned to receive either fluoxetine 20 mg daily or placebo, and followed for 12 months. Participants provided blood and stool samples and completed mental health and QoL questionnaires. Immune functions were assessed by stimulated cytokine secretion [CD3/CD28 stimulation] and flow cytometry for cell type. Linear mixed-effects models were used to compare groups. Results: Of the 26 participants, 14 were randomized to receive fluoxetine and 12 to placebo. Overall, 14 [54%] participants were male. The mean age was 37.4 [SD=13.2] years. Fluoxetine had no effect on inflammatory bowel disease activity measured using either the Crohn’s Disease Activity Index [F(3, 27.5)=0.064, p=0.978] or faecal calprotectin [F(3, 32.5)=1.08, p=0.371], but did have modest effects on immune function. There was no effect of fluoxetine on physical, psychological, social or environmental QoL, anxiety or depressive symptoms as compared to placebo [all p>0.05]. Conclusions: In this small pilot clinical trial, fluoxetine was not superior to placebo in maintaining remission or improving QoL. [ID: ACTRN12612001067864.]
Keywords: Antidepressants; Crohn’s disease; disease activity; mental health; quality of life
Rights: © European Crohn’s and Colitis Organistion (ECCO) 2016. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
RMID: 0030055958
DOI: 10.1093/ecco-jcc/jjw165
Appears in Collections:Psychology publications

Files in This Item:
File Description SizeFormat 
hdl_105164.pdfPublished version120.08 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.